Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOPE-3: Deramiocel in Duchenne Muscular Dystrophy
NCT05126758Phase 3Active, not recruiting
- Sponsor
- Capricor Therapeutics
- Start
- Jun 2022
- Primary completion
- Jun 2025
- Modality
- Mesenchymal Stem Cells, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 3 trial of deramiocel in Duchenne muscular dystrophy (DMD), sponsored by Capricor Therapeutics. Started Jun 2022; status: active, not recruiting.
02
Drugs
deramiocel
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT05126758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05126758.